Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Equity Ratio: 2016-2025

Historic Equity Ratio for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to 0.85.

  • Rocket Pharmaceuticals' Equity Ratio rose 1.75% to 0.85 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.85, marking a year-over-year increase of 1.75%. This contributed to the annual value of 0.88 for FY2024, which is 0.93% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Equity Ratio stood at 0.85, which was up 1.29% from 0.84 recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Equity Ratio ranged from a high of 0.92 in Q3 2021 and a low of 0.83 during Q1 2021.
  • Over the past 3 years, Rocket Pharmaceuticals' median Equity Ratio value was 0.87 (recorded in 2023), while the average stood at 0.87.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Equity Ratio climbed by 27.06% in 2021, and later fell by 7.31% in 2024.
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Equity Ratio stood at 0.91 in 2021, then declined by 3.00% to 0.89 in 2022, then decreased by 1.99% to 0.87 in 2023, then increased by 0.93% to 0.88 in 2024, then increased by 1.75% to 0.85 in 2025.
  • Its last three reported values are 0.85 in Q3 2025, 0.84 for Q2 2025, and 0.87 during Q1 2025.